{"id":15442,"date":"2019-01-18T13:13:28","date_gmt":"2019-01-18T12:13:28","guid":{"rendered":"http:\/\/k2info.w.uib.no\/?p=15442"},"modified":"2019-01-18T13:38:56","modified_gmt":"2019-01-18T12:38:56","slug":"ukens-leder-19","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/en\/2019\/01\/18\/ukens-leder-19\/","title":{"rendered":"[:no]Ukens leder[:en]This week’s editorial[:]"},"content":{"rendered":"

[:no]\"\"<\/a>F\u00f8rst og fremst \u00f8nsker jeg dere alle et godt nytt \u00e5r. Jeg h\u00e5per at planleggingen for det kommende \u00e5ret er godt i gang. Vennligst se informasjon fra Amra, Silke og Eystein under, i forbindelse med kommende s\u00f8knadsprosess og frister denne v\u00e5ren.<\/p>\n

F\u00f8r juleferien fikk jeg muligheten til \u00e5 delta p\u00e5 m\u00f8tet \u00abEATRIS Combined Platform Meeting\u00bb i Slovenia. EATRIS, European Infrastructure for translational medicine konsortium (https:\/\/eatris.eu\/<\/a>), har som m\u00e5l \u00e5 st\u00f8tte forskere (akademia, finansi\u00f8rer, SMB og biotek\/farmasi) i utviklingen av deres biomedisinske oppdagelser til translasjonelle verkt\u00f8y og nyvinninger for bedre helsetjenester. EATRIS har fem hovedplattformer: Biomark\u00f8rer, avbildning og sporing<\/em><\/strong>, sm\u00e5 molekyler, ATMPs<\/strong> og vaksiner. Tanken bak konsortiet er \u00e5 tilrettelegge samarbeidet mellom offentlig og privat sektor, fremskaffe forsknings tjenester og ekspertise, gi regulatorisk<\/em><\/strong> st\u00f8tte, og samarbeide mellom akademia og industri i utviklingen og valideringen av nye verkt\u00f8y. Spesielt til dere som jobber innen disse omr\u00e5dene og planlegger s\u00f8knader til H2020, anbefaler jeg at dere kontakter EATRIS og unders\u00f8ke hvordan de kan bist\u00e5 til \u00e5 knytte kontakt med industrien for videreutviklingen av ideer. Universitetet i Bergen (UiB) er p\u00e5 n\u00e5v\u00e6rende tidspunkt medlem i EATRIS og jeg oppfordrer derfor alle til \u00e5 vurdere denne muligheten til \u00e5 styrke s\u00f8knader eller utviklingen av kommersielle ideer.<\/p>\n

UiB, Haukeland Universitetssykehus, Bergen Teknologioverf\u00f8ring AS (BTO) og Senter for digitalt liv Norge \u00f8nsker \u00e5 informere om et kommende IP seminar som holdes p\u00e5 Bikuben, HUS, mandag 28 januar 2019, mellom 12:30 og 18:30. Med en rekke spennende foredragsholdere, vil dette seminaret engasjere til innovasjon, demonstrere hvordan patentering og publisering kan oppn\u00e5s med suksess, opplyse om hvordan innovasjonen din kan gj\u00f8res betydningsfull, samt presentere og diskutere norske og internasjonale prosjekter. Det er begrenset antall plasser p\u00e5 seminaret, s\u00e5 register deg. Flere detaljer kan du finne her<\/a>. Videre inviterer arrang\u00f8rene publikum til seminar om \u00abStart-up\u00bb og \u00abInnovation mindset\u00bb<\/a> og workshop p\u00e5 temaet \u00abDesign thinking\u00bb<\/a>.<\/p>\n

Til slutt \u00f8nsker jeg \u00e5 minne dere alle p\u00e5 kommende presentasjoner fra Forskerskolen i klinisk medisin (23 januar og 24 januar). K2 er godt representert, s\u00e5 dette er en gyllen mulighet til \u00e5 finne ut av hva dine kollegaer har gjort i 2018.[:en]\"\"<\/a>Firstly Id like to wish you all a happy new year, and I hope that the planning for the research year is well underway and please see Amras, Silkes and Eysteins piece below with respect to upcoming application process and deadlines this spring. <\/span><\/span><\/p>\n

Prior to the Christmas break I had the opportunity to participate in the EATRIS combined platform meeting in Slovenia. <\/span><\/span>EATRIS is the European Research Infrastructure Consortium for Translational Medicine (<\/span>https:\/\/eatris.eu\/<\/a>) and its goal is to support researchers (academia, funders, SME & biotech\/pharma) in developing their biomedical discoveries into novel Translational tools and Interventions for better health outcomes for society. It has 5 platforms of expertise, namely; Biomarkers, imaging and Tracing, small molecules, ATMPs and biologicals, and vaccines. The idea of the consortium to facilitate public-private collaboration and provide research services and access to expertise, provide regulatory support and to collaborate between academia and industry in development and validation of novel tools. In particular for those who are working in these areas and planning H2020 applications I would suggest that you contact Eartris to see if they can help you partner with industry for the development of your ideas. University of Bergen is currently a member so please consider exploiting this opportunity to strengthen your applications or development of your commercial ideas. <\/span><\/span><\/span><\/span><\/p>\n

The University of Bergen, Haukeland University Hospital, Bergen Teknologioverf\u00f8ring AS (BTO), Biomedical Network and Digital life Norway<\/span><\/span> would like to inform you about an IP seminar to be held at Bikuben, Haukeland University Hospital, Monday January 28th 2019, 12:30 -18:30. With a number of exciting speakers this seminar will give you several reasons to engage in innovation, and demonstrate how patenting and publishing both can be successfully achieved, enlighten how to accomplish an impact for your innovation, and\u00a0Norwegian and international projects will be presented and discussed<\/span>. Seats are limited so please register for this event. More details can be found <\/span>here<\/a>. Furthermore, the organizers are inviting a wider audience to <\/span>seminars on Start-ups and Innovation mindset<\/a> and a workshop on <\/span>Design thinking<\/a>.<\/span><\/span><\/span><\/span><\/p>\n

Finally, Id like to remind you about the upcoming research presentations from the Research School in Clinical Medicine (23 – 24.1.) K2 is nicely represented, so a good chance of getting to know what your colleagues have been doing in 2018. <\/span><\/span>[:]<\/p>\n","protected":false},"excerpt":{"rendered":"

[:no]F\u00f8rst og fremst \u00f8nsker jeg dere alle et godt nytt \u00e5r. Jeg h\u00e5per at planleggingen for det kommende \u00e5ret er godt i gang. Vennligst se informasjon fra Amra, Silke og Eystein under, i forbindelse med kommende s\u00f8knadsprosess og frister denne…<\/p>\n

Read more →<\/a><\/p>\n","protected":false},"author":4186,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44,39969],"tags":[],"class_list":["post-15442","post","type-post","status-publish","format-standard","hentry","category-nyheter","category-ukens-leder"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/15442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/users\/4186"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=15442"}],"version-history":[{"count":4,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/15442\/revisions"}],"predecessor-version":[{"id":15446,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/15442\/revisions\/15446"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=15442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/categories?post=15442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/tags?post=15442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}